Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02326584 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT02326584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02326584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2014
Completion date
April 10, 2018
Enrollment
116 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, acute myeloid leukemia